Drugs / Daratumumab and Hyaluronidase-fihj
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT04776018 | Apr 2021 → Aug 2023 | refractory plasma cell neoplasm | Takeda | Terminated | No outcome recorded Stop: Business |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Daratumumab and Hyaluronidase-fihj | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04776018 ↗ |
| Route | Subcutaneous | “Daratumumab and Hyaluronidase-fihj SC injection.” NCT04776018 ↗ |
| Target | CD38 | “Combination of TAK-981 with anti-CD38 antibody daratumumab also resulted in enhanced antitumor activity.” PMID 35226739 ↗ May 2022 |